(firstQuint)Atypical Hemolytic-Uremic Syndrome (aHUS) Registry.

 The study will capture post-marketing safety data on patients treated with eculizumab.

 Additionally, the study will collect information on the progression of disease in all patients.

.

 Atypical Hemolytic-Uremic Syndrome (aHUS) Registry@highlight

Post-marketing safety data on patients treated and untreated with eculizumab.

